Latest news and information from STADA, Thornton & Ross.


Press Release: STADA UK welcomes NICE recommendation of Kinpeygo®▼ (targeted-release budesonide)

First-ever NICE guidance on treating primary IgA nephropathy recommends Kinpeygo® (targeted-release budesonide) capsules as “an acceptable use of NHS resources” in England and Wales.

Find out more about Kinpeygo® (targeted-release budesonide) - request a visit from our Medical Science Liaison Team or Healthcare Partnership Manager Team by clicking here

Prescribing Information can be found here


New NICE Guidance on targeted-release budesonide for primary IgA nephropathy

Read the latest NICE guidance today

Prescribing Information can be found here


Read our summary of all the latest guidance on the use of ranibizumab, including NHS England's August updates

An overview of the latest NHS England recommendations and other guidance supporting the adoption of ranibizumab biosimilars.


STADA Specialty Care

Discover more about a rapidly expanding portfolio of high-quality biosimilar medicines.


For information on our products please visit EMC, and search the product for a Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at: Adverse events should also be reported to Thornton and Ross Limited by emailing or by calling 01484 848164.
UK-MULT-122c(3) | Date of Preparation: February 2024